Integrating biologic therapies into a dermatology practice: Practical and economic considerations

被引：5

作者：

Craze, M ^{[1
]}

Young, M ^{[1
]}

机构：

[1] Texas Dermatol Associates, Dallas, TX 75230 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2003年 / 49卷 / 02期

关键词：

D O I：

10.1016/mjd.2003.558

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

This article discusses the issues involved in the integration of biologic therapies for psoriasis into a dermatology practice. The requirements for staff, space, and other office adaptations are reviewed for infliximab, efalizumab, etanercept, and alefacept in their current injectable forms. Dermatologists will likely elect to offer some or all of these therapies depending on the adjustments necessary within their current practice, patient satisfaction, and the economic possibilities. This article provides information needed to guide dermatology practices in practical decisions regarding the use of biologic therapies.

引用

页码：S139 / S142

页数：4